<DOC>
	<DOC>NCT01232881</DOC>
	<brief_summary>This is a tumor and serum collection study for patients with advanced breast cancer receiving treatment with lonafarnib.</brief_summary>
	<brief_title>Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer</brief_title>
	<detailed_description>OUTLINE: This is a multi-center study. Sample Collection: - Tumor sample - Serum sample Treatment Regimen: - All registered patients must be planning treatment with lonafarnib</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately. Age &gt; 18 years. Planned treatment with lonafarnib for metastatic breast cancer. Must consent to have a biopsy performed to obtain fresh tissue or be able to identify a formalin fixed paraffin embedded (FFPE) tissue block in which tumor samples can be obtained to complete the testing for this study. Planned treatment with any other treatment regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>